REVOLUTIONARY OCT-A

Introducing AngioVue OCT-A

The AngioVue OCT-A system is capable of imaging and displaying function and structure of the ocular microvasculature, through a non-invasive procedure. AngioVue lets you see the retinal vessels in a whole new way. It produces ultra-high resolution, 3D images that are displayed as individual layers of retinal vasculature, allowing you to isolate specific areas of interest and see microvasculature that is not easily seen with FA or ICGA. It allows you to view structural OCT images, such as B-scans and thickness maps, right alongside the OCT-A images. Quick, easy, repeatable and safe, the AngioVue OCT-A enables early intervention and improves clinic workflow.

REVOLUTIONARY OCT-A

Non-invasive & repeatable

This system is very different from traditional angiography such as fluorescein angiography or ICAG, the AngioVue does not require a dye injection (which can be difficult to accomplish on some patients). This enables the clinician to repeat the procedure as many times as necessary, with no risk to the patient. 

REVOLUTIONARY OCT-A

Fast, high-quality images

The AngioVue boasts an image size of 304 x 304 pixels. It can acquire 3 x 3mm, 6 x 6mm and 8 x 8mm retinal scans. Additionally, it can acquire 3 x 3mm and 4.5mm x 4.5mm optic disc scans. It boasts an optical axial resolution of ~5 microns (and a digital pixel sampling = 3 μm).

And its fast... the AngioVue has a high-speed scan acquisition of 70,000 A-scans per second. Its total scan acquisition time (one group) is less than 3 seconds.

 

 

 

 

REVOLUTIONARY OCT-A

HD OCTA Choroidal Neovascularisation

AngioVue offers a large format 6x6mm HD scan for better assessment of large or eccentric CNV membranes extending beyond the central 3x3 mm region (dashed square).

REVOLUTIONARY OCT-A

Visualise all 4 layers of the retina

The AngioVue provides detailed visualisation of the individual layers, including the superficial, deep, outer retina, and choroidal capillaries layers.

Unlike traditional angiography techniques, the AngioVue allows these layers to be isolated with a clarity never before seen. With this type of enhanced imaging, clinicians are able to detect miniscule changes more rapidly, possibly identifying diseases at earlier stages and enabling personalised management of disease progression.

4 ESSENTIAL TECHNOLOGIES

SSADA, DualTrac, En Face & the CUDA Parallel Computing Platform

The AngioVue incorporates four essential technologies to create stunningly detailed images with minimal acquisition and processing time; Split Spectrum Amplitude Decorrelation Angiography (SSADA), DualTrac™ Motion Correction, En Face and the CUDA Parallel Computing Platform.  These multiple technologies enable the AngioVue to produce fast, high-quality images, making it ideal for busy clinical practices.

4 ESSENTIAL TECHNOLOGIES

Split Spectrum Amplitude Decorrelation Angiography (SSADA)

The Split Spectrum Amplitude Decorrelation Angiography (SSADA) algorithm is used to detect motion in vessels. It acquires sequential OCT b-scans at a single cross-section of the retina and compares the scans against one another. The differences between scans indicate the presence of flow.

This unique technology improves image quality by optimising the signal-to-noise ratio, while minimising the scan acquisition time. This SSADA algorithm offers the highest-quality OCT Angiography images available today.

4 ESSENTIAL TECHNOLOGIES

DualTrac Motion Correction

DualTrac Motion Correction is a two-level approach to correcting motion artefacts, resulting from patient movement. The first level provides real-time correction for rapid eye movements, blinking or eye drifting. The second level occurs during post-processing of imaging and corrects smaller levels of motion distortion. This combined approach results in robust motion correction for patients who have trouble directing their focus on a central point during an eye exam, which is essential for high-quality OCT-A imaging. 

4 ESSENTIAL TECHNOLOGIES

En Face visualisation

AngioVue images are three-dimensional and depth-resolved to enable assessment of individual layers of retinal vasculature. En face colourisation uses a standard colour scheme to allow the clinician to identify different retinal layers of interest. The en face layer indicator provides a reference to the retinal layers displayed. 

4 ESSENTIAL TECHNOLOGIES

CUDA Parallel Computing Platform

CUDA dramatically reduces the computation time needed to process images and correct motion artefacts after scan acquisition, making it easy to integrate OCT-A imaging into the practice workflow. With CUDA, images load in seconds, not minutes.

UNIQUE SOFTWARE

AngioAnalytics, the world’s first OCT-A quantification tool

AngioAnalytics is the World's only OCT angiography-based quantification of ocular blood flow, providing the clinician with objective data. This software is unique to the AngioVue OCT-A device and offers a number of tools to measure and quantify flow, non-flow and flow density.

UNIQUE SOFTWARE

Measure & quantify flow, non-flow and flow density

The flow area measurement quantifies an area of vascularisation in a user-defined region of interest. The non-flow area measurement quantifies an avascular area defined by automatic border detection.  

UNIQUE SOFTWARE

Choose & quantify

The user can choose as many non-flow areas as they like, and the tool will quantify the cumulative non-flow area. Flow density map assesses and compares the relative density of flow as a percentage of the total area.

WIDER FIELD OF VIEW

AngioMontageHD – providing a wide-field view of the retinal microvasculature

AngioMontageHD instantly combines macula and optic disc images for high-density widefield visualization (10x6 mm). 

WIDER FIELD OF VIEW

Improves visualisation of abnormalities

AngioMontageHD instantly combines macula and optic disc images for high-density widefield visualisation (10x6 mm). This unprecedented display of microvasculature enables assessment of the essential part of the retina to aid in the early diagnosis and management of sight-threatening diseases.

New AngioVue Retina

The AngioVue Retina option

AngioVue Retina offers a unique platform specifically designed for retina applications. It integrates state-of-the-art OCT-A with a full suite of retina scans. The AngioVue Retina option allows you to expand your imaging capacity, bringing valuable new clinical information without replacing your existing OCT device. It enables you to purchase the OCT-A functionality that you need, with the option of upgrading to a full AngioVue system (which includes glaucoma and anterior segment capabilities) at any time. 

New AngioVue Retina

System features

AngioVue Retina boasts the following features; AngioRetina, AngioDisc, AngioAnalytics and a full suite of retina scans. The scans include; Line, HD line, cross line, grid, raster, retina map, 3D retina, 3D wide-field and 3D wide-field with MCT. 

WATCH THE WEBINARS

Integrating AngioVue OCT-Angiography into daily clinical practice

This webinar, hosted by The Ophthalmologist, includes contributions from two of the pioneers of OCT Angiography (OCT-A), Maddalena Quaranta-El Mafouthi and Adil El Maftouhi from the Centre Rabelais, Lyon, France.

Maddalena and Adil were among the first retina specialists in the World to adopt OCTA, with over 2 years experience using AngioVue OCTA. They have played a pivotal role, working alongside both the OCT imaging industry and pharmaceutical companies, in ensuring that OCT-A is a user and patient-friendly addition to the ophthalmologist's diagnostic armamentarium. 

Please note, you will need to register to watch this webinar, which has a duration of 1 hour 28 minutes.

WATCH THE WEBINARS

The role of AngioVue OCT-Angiography in the management of AMD

Two OCT-A pioneers, Prof. Bruno Lumbroso and Dr Marco Rispoli from the Centro Oftalmologico Meterraneo, Italy, give practical advice in this webinar for using OCTA to manage patients with AMD in your own practice. With more than two years experience using AngioVue OCTA, along with numerous publications and books on the subject, they are recognized as having played a pivotal role in leading both the clinical validation of OCTA, and in defining the OCTA educational standards for the Ophthalmology community. 

Please note, you will need to register to watch this webinar, which has a duration of 54 minutes.